Immunotherapy

After chemotherapy, immunotherapy has become the standard treatment for bladder cancer. Will it ever play a bigger role?

While there is currently no definitive way to predict who will respond and who will not, researchers at Brighton and Sussex Medical School in the United Kingdom are working on a blood test that could identify about half of those who may not.

In recent years, immunotherapy has been falling flat in the brain cancer field, but recent research may change that.

Patients who receive anti-PD-1 therapies may experience delayed cutaneous side effects like lesions, eczema or psoriasis, even after treatment has ended.

In this week’s episode of CURE® Talks Cancer, we delve into immunotherapy breakthroughs and how a new series of patient summits can help individuals learn more.

Take a look at the top five CURE stories of July 2018 in this video. 

Because little is known about the effect of patients' sex on the efficacy of immune checkpoint inhibitors as cancer treatments, the researchers performed a systematic review and meta-analysis to determine the heterogeneity of immune checkpoint inhibitor efficacy between men and women.

What are the different types of immunotherapy and, importantly, what are fellow patients saying about them?

We spoke with veteran journalist Neil Canavan about his book, A Cure Within: Scientists Unleashing the Immune System to Kill Cancer. 

Checkpoint inhibitors — immunotherapy drugs that are improving the treatment landscape for many patients across the spectrum of cancers — are relatively new. The science involved in finding and treating the patients most likely to respond to these drugs — without overlooking any or treating those who won’t benefit — is even newer.